WO2022017929A1 - Utilisation de cannabidiol dans le traitement de crises associées à la lissencéphalie - Google Patents

Utilisation de cannabidiol dans le traitement de crises associées à la lissencéphalie Download PDF

Info

Publication number
WO2022017929A1
WO2022017929A1 PCT/EP2021/069856 EP2021069856W WO2022017929A1 WO 2022017929 A1 WO2022017929 A1 WO 2022017929A1 EP 2021069856 W EP2021069856 W EP 2021069856W WO 2022017929 A1 WO2022017929 A1 WO 2022017929A1
Authority
WO
WIPO (PCT)
Prior art keywords
cbd
preparation
seizures
thc
cannabinoids
Prior art date
Application number
PCT/EP2021/069856
Other languages
English (en)
Inventor
Daniel Adam CHECKETTS
Kevin James CRAIG
Original Assignee
GW Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Limited filed Critical GW Research Limited
Publication of WO2022017929A1 publication Critical patent/WO2022017929A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Definitions

  • the present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes.
  • CBD cannabidiol
  • the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with Lissencephaly.
  • the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 95% of the total extract (w/w) and the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w).
  • the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. More preferably the other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w).
  • the botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.
  • the other cannabinoids present are THC at a concentration of about 0.01% to about 0.1% (w/w); CBD-C1 at a concentration of about 0.1% to about 0.15% (w/w); CBDV at a concentration of about 0.2% to about 0.8% (w/w); and CBD-C4 at a concentration of about 0.3% to about 0.4% (w/w).
  • THC is present at a concentration of about 0.02% to about 0.05% (w/w).
  • the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form.
  • Epilepsy occurs in approximately 1% of the population worldwide, (Thurman et al., 2011) of which 70% are able to adequately control their symptoms with the available existing anti-epileptic drugs (AED). However, 30% of this patient group, (Eadie etal., 2012), are unable to obtain seizure freedom from the AED that are available and as such are termed as suffering from intractable or “treatment-resistant epilepsy” (TRE).
  • TRE treatment-resistant epilepsy
  • Intractable or treatment-resistant epilepsy was defined in 2009 by the International League against Epilepsy (I LAE) as “failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom ” (Kwan et al., 2009).
  • Childhood epilepsy is a relatively common neurological disorder in children and young adults with a prevalence of approximately 700 per 100,000. This is twice the number of epileptic adults per population.
  • the main symptom of epilepsy is repeated seizures.
  • Clinical observations and electroencephalography (EEG) tests are conducted and the type(s) of seizures are classified according to the ILEA classification.
  • Generalized seizures where the seizure arises within and rapidly engages bilaterally distributed networks, can be split into six subtypes: tonic-clonic (grand mal) seizures; absence (petit mal) seizures; clonic seizures; tonic seizures; atonic seizures and myoclonic seizures.
  • Focal (partial) seizures where the seizure originates within networks limited to only one hemisphere, are also split into sub-categories.
  • the seizure is characterized according to one or more features of the seizure, including aura, motor, autonomic and awareness / responsiveness.
  • a seizure begins as a localized seizure and rapidly evolves to be distributed within bilateral networks this seizure is known as a bilateral convulsive seizure, which is the proposed terminology to replace secondary generalized seizures (generalized seizures that have evolved from focal seizures and are no longer remain localized).
  • focal seizures with impairment Focal seizures where the subject’s awareness / responsiveness is altered are referred to as focal seizures with impairment and focal seizures where the awareness or responsiveness of the subject is not impaired are referred to as focal seizures without impairment.
  • Lissencephaly which literally means “smooth brain,” is a rare, gene-linked brain malformation characterized by the absence of normal convolutions in the cerebral cortex and an abnormally small head (microcephaly). 1 It is caused by defective neuronal migration during embryonic development. Symptoms may include unusual facial appearance, difficulty swallowing, failure to thrive, muscle spasms, seizures, severe psychomotor retardation, and hands, fingers, or toes may be deformed.
  • CBD Cannabidiol
  • An article in 2017 4 describes the use of CBD hemp oil in the treatment of seizures associated with Lissencephaly in conjunction with various anti-epileptic drugs.
  • the description of the product "Palmetto Harmony” states that the product is made with two ingredients, MCT oil and hemp flower extract, and that it contains a full-spectrum terpene profile.
  • a presentation by Salyer in 2019 5 describes a single case whereby the off-label use of Epidolex was trialled in the treatment of seizures associated with Lissencephaly in combination with various antiepileptic drugs. There is no mention or suggestion of the types of seizures treated with the drug.
  • WO 2019/145700, WO 2015/193668 and WO 2016/203239 are the applicant’s previous patent applications which are directed to highly purified CBD for use in the treatment of seizures in treatment-resistant epilepsy in combination with anti-epileptic drugs. There is no disclosure of the specific disease indication, Lissencephaly, in any of the documents.
  • CBD cannabidiol
  • the seizures associated with Lissencephaly are atonic, tonic, tonic-clonic, myoclonic and absence seizures.
  • the CBD preparation comprises greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC).
  • the CBD preparation comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids, wherein the less than or equal to 2% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); cannabidiol- C1 (CBD-C1); cannabidivarin (CBDV); and cannabidiol-C4 (CBD-C4), and wherein the THC is present as a mixture of trans-THC and cis-THC.
  • THC cannabinoids tetrahydrocannabinol
  • CBD-C1 cannabidiol- C1
  • CBDDV cannabidivarin
  • CBD-C4 cannabidiol-C4
  • the CBD preparation is used in combination with one or more concomitant anti-epileptic drugs (AED).
  • AED concomitant anti-epileptic drugs
  • the one or more AED is selected from the group consisting of: valproic acid, levetiracetam, clobazam, vigabatrin, zonisamide, lacosamide, zonisamide and phenobarbital.
  • the CBD is present is isolated from cannabis plant material.
  • the CBD is present as a synthetic preparation.
  • the dose of CBD is greater than 5 mg/kg/day. More preferably the dose of CBD is 20 mg/kg/day. More preferably the dose of CBD is 25 mg/kg/day.
  • a method of treating seizures associated with Lissencephaly comprising administering a cannabidiol (CBD) preparation to the subject in need thereof.
  • CBD cannabidiol
  • cannabinoids Over 100 different cannabinoids have been identified, see for example, Handbook of Cannabis, Roger Pertwee, Chapter 1, pages 3 to 15. These cannabinoids can be split into different groups as follows: Phytocannabinoids; Endocannabinoids and Synthetic cannabinoids (which may be novel cannabinoids or synthetically produced phytocannabinoids or endocannabinoids).
  • phytocannabinoids are cannabinoids that originate from nature and can be found in the cannabis plant.
  • the phytocannabinoids can be isolated from plants to produce a highly purified extract or can be reproduced synthetically.
  • “Highly purified cannabinoids” are defined as cannabinoids that have been extracted from the cannabis plant and purified to the extent that other cannabinoids and non-cannabinoid components that are co-extracted with the cannabinoids have been removed, such that the highly purified cannabinoid is greater than or equal to 95% (w/w) pure.
  • Synthetic cannabinoids are compounds that have a cannabinoid or cannabinoid-like structure and are manufactured using chemical means rather than by the plant.
  • Phytocannabinoids can be obtained as either the neutral (decarboxylated form) or the carboxylic acid form depending on the method used to extract the cannabinoids. For example, it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate into the neutral form.
  • Treatment-resistant epilepsy (TRE) or “intractable epilepsy” is defined as per the I LAE guidance of 2009 as epilepsy that is not adequately controlled by trials of one or more AED.
  • Atonic seizures also known as drop attacks, occur when a person suddenly loses muscle tone resulting in their head or body possibly going limp. In some children, only their head drops suddenly. They can begin in one area or side of the brain (focal onset) or both sides of the brain (generalized onset).
  • Tonic seizures can be generalised onset, affecting both sides of the brain, or they can be focal onset, starting in just one side of the brain. If a tonic seizure starts in both sides of the brain, all muscles tighten and the subject’s body goes stiff. If standing, they may fall to the floor, their neck may extend, eyes open wide and roll upwards, whilst their arms may raise upwards and legs stretch or contract. If a tonic seizure starts in one side of the brain muscles tighten in just one area of the body. Tonic seizures usually last less than one minute.
  • Tonic-clonic seizures (also called convulsions) has replaced the term “grand mal.”
  • a subject experiences a tonic-clonic seizure they lose consciousness, muscles stiffen, and jerking movements are seen.
  • This type of seizure usually lasts 1 to 3 minutes and takes longer for the subject to recover. It usually begins on both sides of the brain but can start in one side and spread to the whole brain.
  • Myoclonic seizures are brief shock-like jerks of a muscle or group of muscles which can occur in a variety of epilepsy syndromes that have different characteristics. During a myoclonic seizure, the subject is usually awake and able to think clearly. Such seizures usually do not last more than a second or two and whilst there can be just one, sometimes many will occur within a short time.
  • Absence seizures has replaced the term “petit mal seizures.” Absence seizures cause lapses in awareness, sometimes with staring, and are more common in children. They begin and end abruptly, lasting only a few seconds. Such seizures can be so brief they sometimes are mistaken for daydreaming and may not be detected for months. They are a type of generalized onset seizures, meaning they begin in both sides of the brain at the same time.
  • “Focal seizures with impairment” usually start in a small area of the temporal lobe or frontal lobe of the brain and involve other areas of the brain within the same hemisphere that affect alertness and awareness. Most subjects experience automatisms during a focal seizure with impaired consciousness.
  • the drug substance used is a liquid carbon dioxide extract of high-CBD containing chemotypes of Cannabis sativa L. which had been further purified by a solvent crystallization method to yield CBD.
  • the crystallisation process specifically removes other cannabinoids and plant components to yield greater than or equal to 95% CBD.
  • CBD is highly purified because it is produced from a cannabis plant rather than synthetically there is a small number of other cannabinoids which are co-produced and co-extracted with the CBD. Details of these cannabinoids and the quantities in which they are present in the medication are as described in Table A below.
  • the drug substance used in the trials is a liquid carbon dioxide extract of high-CBD containing chemotypes of Cannabis sativa L. which had been further purified by a solvent crystallization method to yield CBD.
  • the crystallisation process specifically removes other cannabinoids and plant components to yield greater than 95% CBD w/w, typically greater than 98% w/w.
  • Cannabis sativa L. plants are grown, harvested, and processed to produce a botanical extract (intermediate) and then purified by crystallization to yield the CBD (botanically derived purified CBD).
  • the plant starting material is referred to as Botanical Raw Material (BRM); the botanical extract is the intermediate; and the active pharmaceutical ingredient (API) is CBD, the drug substance.
  • BRM Botanical Raw Material
  • API active pharmaceutical ingredient
  • Table B CBD botanical raw material specification
  • the purity of the botanically derived purified CBD preparation was greater than or equal to 98%.
  • the botanically derived purified CBD includes THC and other cannabinoids, e.g., CBDA, CBDV, CBD-C1 , and CBD-C4.
  • the CBD preparation comprises not more than 0.15% THC based on total amount of cannabinoid in the preparation. In some embodiments, the CBD preparation comprises about 0.01% to about 0.1% THC based on total amount of cannabinoid in the preparation. In some embodiments, the CBD preparation comprises about 0.02% to about 0.05% THC based on total amount of cannabinoid in the preparation.
  • the CBD preparation comprises about 0.2% to about 1.0% CBDV based on total amount of cannabinoid in the preparation. In some embodiments, the CBD preparation comprises about 0.2% to about 0.8% CBDV based on total amount of cannabinoid in the preparation. [0059] In some embodiments, the CBD preparation comprises about 0.3% to about 0.5%
  • CBD-C4 based on total amount of cannabinoid in the preparation.
  • the CBD preparation comprises about 0.3% to about 0.4% CBD-C4 based on total amount of cannabinoid in the preparation.
  • the CBD preparation comprises about 0.1% to about 0.15% CBD-C1 based on total amount of cannabinoid in the preparation.
  • Distinct chemotypes of the Cannabis sativa L. plant have been produced to maximize the output of the specific chemical constituents, the cannabinoids. Certain chemovars produce predominantly CBD. Only the (-)-trans isomer of CBD is believed to occur naturally. During purification, the stereochemistry of CBD is not affected.
  • High CBD chemovars were grown, harvested, dried, baled and stored in a dry room until required.
  • the botanical raw material (BRM) was finely chopped using an Apex mill fitted with a 1 mm screen. The milled BRM was stored in a freezer prior to extraction.
  • the BDS produced using the methodology above was dispersed in C5-C12 straight chain or branched alkane.
  • the mixture was manually agitated to break up any lumps and the sealed container then placed in a freezer for approximately 48 hours.
  • the crystals were isolated via vacuum filtration, washed with aliquots of cold C5-C12 straight chain or branched alkane, and dried under a vacuum of ⁇ 10mb at a temperature of 60°C until dry.
  • the botanically derived purified CBD preparation was stored in a freezer at -20°C in a pharmaceutical grade stainless steel container, with FDA food grade approved silicone seal and clamps.
  • the botanically derived purified CBD used in the clinical trial described in the invention comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids.
  • the other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w).
  • the botanically derived purified CBD used additionally comprises a mixture of both trans-THC and cis-THC. It was found that the ratio of the trans-THC to cis-THC is altered and can be controlled by the processing and purification process, ranging from 3.3:1 (trans-THC:cis- THC) in its unrefined decarboxylated state to 0.8:1 (trans-THC:cis-THC) when highly purified. [0070] Furthermore, the cis-THC found in botanically derived purified CBD is present as a mixture of both the (+)-cis-THC and the (-)-cis-THC isoforms.
  • CBD preparation could be produced synthetically by producing a composition with duplicate components.
  • Example 1 describes the use of a botanically derived purified CBD in an open label, expanded-access program to investigate the clinical efficacy and safety of purified pharmaceutical cannabidiol formulation (CBD) in the treatment of Lissencephaly.
  • CBD cannabidiol formulation
  • EXAMPLE 1 CLINICAL EFFICACY AND SAFETY OF PURIFIED PHARMACEUTICAL CANNABIDIOL (CBD) IN THE TREATMENT OF PATIENTS DIAGNOSED WITH LISSENCEPHALY
  • Subjects were required to be on one or more AEDs at stable doses for a minimum of two weeks prior to baseline and to have stable vagus nerve stimulation (VNS) settings and ketogenic diet ratios for a minimum of four weeks prior to baseline.
  • VNS vagus nerve stimulation
  • a maximum dose of 50 mg/kg/day could be utilised for patients who were tolerating the medication but had not achieved seizure control; these patients had further weekly titration by 5mg/kg/day.
  • Seizure frequency, intensity, and duration were recorded by caregivers in a diary during a baseline period of at least 28 days. Changes in seizure frequency relative to baseline were calculated after at least 2 weeks and at defined timepoints of treatment.
  • Patients may be defined as responders if they had more than 50% reduction in seizure frequency compared to baseline.
  • the percent change in seizure frequency was calculated as follows:
  • % change ((weekly seizure frequency time interval)-( weekly seizure frequency Baseline)) x100 seizure (weekly seizure frequency Baseline) frequency
  • the percent change of seizure frequency may be calculated for any time interval where seizure number has been recorded.
  • the percent change of seizure frequency for the end of the treatment period was calculated as follows:
  • % reduction ((weekly seizure frequency Baseline) - (weekly seizure frequency End)) x100 seizure frequency (weekly seizure frequency Baseline)
  • VPA valproic acid
  • LEV levetiracetam
  • CLB clobazam
  • VGB vigabatrin
  • ZNS zonisamide
  • LCS lacosamide
  • ZNS zonisamide
  • PHB phenobarbital
  • RFN rufinamide
  • All five patients were given at least 5 mg/kg/day of CBD, four patients were titrated up to 25 mg/kg/day (#2, 3, 5, 6) and one patient was titrated up to 45 mg/kg/day (#6).
  • the average number of concomitant AEDs at the time of starting CBD was three per patient (range: 1-4, median: 3).
  • Tables 2A-F illustrate the seizure frequency for each patient as well as the dose of
  • Table 2A Seizure frequency data for Patient 1
  • Patient 4 was treated for 24 weeks and experienced a 36.8% reduction in tonic seizures, a 61.5% reduction in tonic-clonic seizures, a 35.0% reduction in myoclonic seizures and a 5.2% reduction in absence seizures over the treatment period.
  • Patient 5 was treated for 8 weeks and experienced a 71.4% reduction in tonic seizures and an 87.5% reduction in tonic-clonic seizures over the treatment period.
  • CBD was effective in reducing the frequency of the following seizure types: atonic, tonic, tonic-clonic, myoclonic and absence.
  • Palmetto Harmony (2017) "Fighting Lissencephaly: Harmony's Story” https://palmettoharmony.com/blog/2017 /02/10/fighting-lissencephalyharmonys-story/

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Informatics (AREA)

Abstract

La présente invention concerne l'utilisation du cannabidiol (CBD) pour le traitement de crises associées à des syndromes épileptiques rares. En particulier, les crises associées aux syndromes épileptiques rarer qui sont traitées sont celles qui sont rencontrées chez des patients chez lesquels une lissencéphalie a été diagnostiquée. Dans un autre mode de réalisation, les types de crises comprennent les crises atoniques, toniques, tonico-cloniques, myocloniques et d'absence.
PCT/EP2021/069856 2020-07-20 2021-07-15 Utilisation de cannabidiol dans le traitement de crises associées à la lissencéphalie WO2022017929A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2011125.8A GB2597283A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2011125.8 2020-07-20

Publications (1)

Publication Number Publication Date
WO2022017929A1 true WO2022017929A1 (fr) 2022-01-27

Family

ID=72339052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/069856 WO2022017929A1 (fr) 2020-07-20 2021-07-15 Utilisation de cannabidiol dans le traitement de crises associées à la lissencéphalie

Country Status (2)

Country Link
GB (1) GB2597283A (fr)
WO (1) WO2022017929A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193668A1 (fr) 2014-06-17 2015-12-23 Gw Pharma Limited Utilisation de cannabidiol dans le traitement de l'épilepsie
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2016203239A1 (fr) 2015-06-17 2016-12-22 GW Research Limited Utilisation de cannabinoïdes dans le traitement de l'épilepsie
WO2019145700A1 (fr) 2018-01-24 2019-08-01 GW Research Limited Utilisation de cannabinoïdes dans le traitement de l'épilepsie
WO2019207319A1 (fr) * 2018-04-27 2019-10-31 GW Research Limited Préparations de cannabidiol et leurs utilisations
WO2020234569A1 (fr) * 2019-05-23 2020-11-26 GW Research Limited Utilisation de cannabidiol dans le traitement de spasmes épileptiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193668A1 (fr) 2014-06-17 2015-12-23 Gw Pharma Limited Utilisation de cannabidiol dans le traitement de l'épilepsie
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2016203239A1 (fr) 2015-06-17 2016-12-22 GW Research Limited Utilisation de cannabinoïdes dans le traitement de l'épilepsie
WO2019145700A1 (fr) 2018-01-24 2019-08-01 GW Research Limited Utilisation de cannabinoïdes dans le traitement de l'épilepsie
WO2019207319A1 (fr) * 2018-04-27 2019-10-31 GW Research Limited Préparations de cannabidiol et leurs utilisations
WO2020234569A1 (fr) * 2019-05-23 2020-11-26 GW Research Limited Utilisation de cannabidiol dans le traitement de spasmes épileptiques

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANON: "Lissencephaly -Harmony's Story", 10 February 2017 (2017-02-10), XP055853918, Retrieved from the Internet <URL:https://palmettoharmony.com/blog/2017/02/10/fighting-lissencephaly-harmonys-story/> [retrieved on 20211022] *
CANNABIS COMPOUND FOUND TO HELP CHILD WITH SEIZURES, 2014, pages 3 - 15, Retrieved from the Internet <URL:https://www.latimes.com/socal/qlendale-news-press/news/tn-qnP-cannabis-compound-found-to-help-child-with-seizures-20141231-story.html>
CARABALLO ROBERTO ET AL: "Effectiveness of cannabidiol in a prospective cohort of children with drug-resistant epileptic encephalopathy in Argentina", SEIZURE, BAILLIERE TINDALL, LONDON, GB, vol. 80, 6 June 2020 (2020-06-06), pages 75 - 80, XP086246226, ISSN: 1059-1311, [retrieved on 20200606], DOI: 10.1016/J.SEIZURE.2020.06.005 *
HERLOPIAN ALINE ET AL: "Cannabidiol in treatment of refractory epileptic spasms: An open-label study", EPILEPSY AND BEHAVIOR, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 106, 10 March 2020 (2020-03-10), XP086148260, ISSN: 1525-5050, [retrieved on 20200310], DOI: 10.1016/J.YEBEH.2020.106988 *
HERNANDEZ ERICA: "Local family speaks about how medical cannabis has helped their son", 16 May 2019 (2019-05-16), XP055853923, Retrieved from the Internet <URL:https://www.ksat.com/health/2019/05/16/local-family-speaks-about-how-medical-cannabis-has-helped-their-son/#:~:text=SAN%20ANTONIO%20%E2%80%93%20As%20the%20Texas,they%20give%20to%20their%20son.&text=Dawson%20qualified%20to%20get%20medicine,The%20results%20were%20astonishing.> [retrieved on 20211022] *
LOCAL FAMILY SPEAKS ABOUT HOW MEDICAL CANNABIS HAS HELPED THEIR SON, 2019, Retrieved from the Internet <URL:https:llwww.ksat.com/health/2019/05/16/1ocal-famiIv-speaks-about-how-medica1-cannabis-has-helped-their-son/>
MIKAILIAN ARIN: "Cannabis compound found to help child with seizures - Los Angeles Times", 31 December 2014 (2014-12-31), XP055835258, Retrieved from the Internet <URL:https://www.latimes.com/socal/glendale-news-press/news/tn-gnp-cannabis-compound-found-to-help-child-with-seizures-20141231-story.html> [retrieved on 20210826] *
PALMETTO HARMONY, FIGHTING LISSENCEPHALY: HARMONY'S STORY, 2017, Retrieved from the Internet <URL:https://palmettoharmony.com/blog/2017/02/10/fighting-lissencephalyharmonys-story>
SALYER, AVERY LISSENCEPHALY SEIZURES & CBD OIL, 2019, Retrieved from the Internet <URL:https://www.bexarcountypasociety.org/mwginternal/de5fs23hu73ds/progress?id=p4-kEe8302bC8zoY7QjRHy-7GcQviWdRAsXHRcYuUx4,&dl>

Also Published As

Publication number Publication date
GB202011125D0 (en) 2020-09-02
GB2597283A (en) 2022-01-26

Similar Documents

Publication Publication Date Title
AU2020279889A1 (en) Use of cannabidiol in the treatment of epileptic spasms
EP4182024A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des mutations dans le gène syngap1
EP4181899A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
WO2022017929A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à la lissencéphalie
WO2022017958A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées au syndrome du bébé secoué
WO2022017915A1 (fr) Cannabidiol destiné à être utilisé dans le traitement de crises associées à des lésions cérébrales
WO2022017950A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à la sclérose temporale mésiale bilatérale
WO2022017930A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées au syndrome de jeavon
EP4181888A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau
WO2022017925A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées au syndrome épileptique multifocal
WO2022017917A1 (fr) Cannabidiol destiné à être utilisé dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau
WO2022017954A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau
WO2022017919A1 (fr) Cannabidiol destiné à être utilisé dans le traitement de crises associées à une hydrocéphalie
EP4181902A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
WO2022017944A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à une dégénérescence cérébrale bilatérale
WO2022017945A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
WO2022017955A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau
WO2022017931A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées au syndrome d&#39;ohtahara ou au syndrome d&#39;ohtahara secondaire à une mutation d&#39;aimp1
WO2022017957A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à un accident vasculaire cérébral ou à une hémorragie cérébrale
WO2022017926A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes d&#39;épilepsie rare associés à des anomalies génétiques
WO2022017913A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
WO2022017946A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies génétiques
EP4181890A1 (fr) Utilisation du cannabidiol dans le traitement de crises associées au syndrome de rett
WO2022017963A1 (fr) Utilisation de cannabidiol dans le traitement de crises d&#39;épilepsie associées à une encéphalite
WO2022017920A1 (fr) Cannabidiol destiné à être utilisé dans le traitement de crises associées à des syndromes épileptiques rares liés à des anomalies structurales du cerveau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21751984

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21751984

Country of ref document: EP

Kind code of ref document: A1